Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma

BACKGROUND: Relapsed/refractory peripheral T‐cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. AIM: We report outcomes of Bv‐ICE in CD30 (+) and Ro‐ICE in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentille, Cesar, Sarfraz, Humaira, Joshi, Jitesh, Randhawa, Jasleen, Shah, Shilpan, Pingali, Sai Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327648/
https://www.ncbi.nlm.nih.gov/pubmed/35263030
http://dx.doi.org/10.1002/cnr2.1581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327648/
https://www.ncbi.nlm.nih.gov/pubmed/35263030
http://dx.doi.org/10.1002/cnr2.1581

Ejemplares similares